bioMérieux Received IVDR Class D Certification
The company earned the European Union's highest safety classification for its respiratory testing panels.
Updated on Sept. 22, 2026 in Diseases — General
Live Poll
Do you believe faster diagnostic testing for high-risk pathogens improves your own access to healthcare?
bioMérieux has secured IVDR Class D CE marking for its BIOFIRE Respiratory 2.1 plus and BIOFIRE FILMARRAY Pneumonia plus panels. This certification represents the highest risk classification under European In Vitro Diagnostic Regulation, largely due to the inclusion of MERS-CoV on the test menus.
Why it matters
The certification process ensures that diagnostic tools identifying high-risk pathogens meet stringent safety and performance standards for public health protection. By achieving this status, the company ensures its syndromic testing capabilities remain compliant for broad use across the European market.
The BIOFIRE Respiratory 2.1 plus panel detects upper respiratory infections in approximately 45 minutes, while the BIOFIRE FILMARRAY Pneumonia plus panel identifies lower respiratory tract infections in about 1 hour. No design modifications were required for the approval.
The players
bioMérieux
This is a French multinational biotechnology company that specializes in in vitro diagnostics for clinical and industrial applications.
The details
The certified panels utilize syndromic testing to simultaneously identify various bacterial and viral pathogens as well as key antimicrobial resistance markers from a single patient sample. These devices are intended for detecting pathogens that pose a high risk to public health, specifically including the Middle East Respiratory Syndrome Coronavirus.
Timeline
September 22, 2026: bioMérieux announced the IVDR Class D certification.
Early 2027: The certified panels will become available on the European market.
The Big Picture
This development follows the implementation of the European Union's In Vitro Diagnostic Regulation (IVDR), which requires higher scrutiny for diagnostic devices. This regulatory shift forces manufacturers to meet rigorous standards for high-risk pathogen detection, impacting the availability of diagnostic tools across the region.
The availability of these diagnostic panels ensures that healthcare providers can quickly identify respiratory pathogens and resistance markers. This expedited testing allows for more precise treatment decisions, potentially improving patient outcomes by reducing the time required to diagnose infections.
The takeaway
The Class D designation underscores the critical role of stringent regulatory oversight in the clinical laboratory space. Healthcare systems utilizing these diagnostic tools can rely on validated, high-risk pathogen detection protocols that support rapid and accurate clinical management.
Further reading
For more information on diagnostic advancements, visit Diseases — General.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you believe faster diagnostic testing for high-risk pathogens improves your own access to healthcare?
